A phase I study to investigate the antitumor activity of ADCT-402, an anti-CD19 PBD-conjugate, in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma (B-cell NHL).

Trial Profile

A phase I study to investigate the antitumor activity of ADCT-402, an anti-CD19 PBD-conjugate, in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma (B-cell NHL).

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2015

At a glance

  • Drugs ADCT 402 (Primary)
  • Indications B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Dec 2015 New trial record
    • 05 Dec 2015 According to the ADC Therapeutics media release, FDA granted IND clearance to begin phase I clinical trials with ADCT-402 in hematological tumors.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top